Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE II
NCT06436274Phase 4Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Massachusetts General Hospital. Started Oct 2024; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06436274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436274.